Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy
Neurogastroenterology & Motility · 2024
DOI: 10.1111/nmo.14857 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, 2024. Verfasst von Revati Varma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Ondansetron, Gastric Emptying. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
This study compared the effects of ondansetron and placebo in patients with diabetes mellitus and symptoms of dyspepsia (diabetic gastroenteropathy [DGE]).
Methods
We performed a randomized, double‐blinded, placebo‐controlled study of ondansetron tablets (8 mg) three times daily for 4 weeks in DGE patients. Symptoms were assessed with the Gastroparesis Cardinal Symptom Index daily diaries. Gastric emptying (GE) of solids (scintigraphy) and duodenal lipid infusions (300 kcal over 2 h) were each assessed twice, with placebo and ondansetron. Drug effects on GE, symptoms during the GE study and during lipid infusion, and daily symptoms were analyzed. Key Results Of 41 patients, 37 completed both GE studies and one completed 1; 31 completed both lipid infusions and four only placebo; and all 35 randomized patients completed 4 weeks of treatment. Compared to placebo, ondansetron reduced the severity of fullness ( p = 0.02) and belching ( p = 0.049) during lipid infusion but did not affect GE T 1/2 . Both ondansetron and placebo improved daily symptoms versus the baseline period ( p < 0.05), but the differences were not significant. In the analysis of covariance of daily symptoms during the treatment period, the interaction term between treatment and the acute effect of ondansetron on symptoms during lipid challenge was significant ( p = .024). Conclusions & Inferences Ondansetron significantly reduced fullness during enteral lipid infusion in patients with DGE. Overall, ondansetron did not improve daily symptoms versus placebo. But patients in whom ondansetron improved symptoms during enteral lipid challenge were perhaps more likely to experience symptom relief during daily treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Adil E Bharucha
Förderung
- NIDDK NIH HHS
Zitieren
APA
Varma, R., Chakraborty, S. C., Ramu, S. K., Burton, D. D., Deb, B., Ryks, M. D., Feuerhak, K. J., Bailey, K. R., & Bharucha, A. E. (2024). Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14857
Vancouver
Varma R, Chakraborty SC, Ramu SK, Burton DD, Deb B, Ryks MD, et al. Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14857
BibTeX
@article{Varma2024,
author = {Varma, Revati and Chakraborty, Subhankar C and Ramu, Shivabalan Kathavarayan and Burton, Duane D and Deb, Brototo and Ryks, Michael D and Feuerhak, Kelly J and Bailey, Kent R and Bharucha, Adil E},
title = {Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy},
journal = {Neurogastroenterology & Motility},
year = {2024},
doi = {10.1111/nmo.14857}
}
EUVIMED